Commercial Credit Report for Uwell Biopharma Inc

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Uwell Biopharma Inc is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Uwell Biopharma Inc

Phone: +886 226972200p:+886 226972200	NEW TAIPEI, 221 Taiwan	Ticker: 79027902

Business Summary

Uwell Biopharma Inc is a Taiwan-based company primarily engaged in the development of novel drugs for gene-modified cell therapy. The Company focuses on chimeric antigen receptor T-cell (CAR-T) therapy, with its main product being Welgenaleucel (UWC19), primarily indicated for relapsed/refractory non-Hodgkin's B-cell lymphoma and acute/chronic lymphocytic leukemia; Anti-human epidermal growth factor receptor 2 (HER2) CAR-T, primarily indicated for HER2-positive breast cancer, pancreatic cancer, colorectal cancer, and ovarian cancer; and lentiviral vector production, capable of designing and optimizing vectors according to different chimeric antigen receptor (CAR) structural requirements to ensure high-efficiency gene delivery and batch-to-batch stability. The Company's products are currently in clinical trials and have not yet entered the market.

(Source: Company's Website)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2025	12/31/2024	-	-	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research

General Information

Number of Employees:	23	(As of 6/30/2025)
Outstanding Shares:	200,000,000	(As of 6/30/2025)
Stock Exchange:	TPO
Fax Number:	+886 226972255

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN